Serological follow up of positive SARS-CoV-2 cases
DOI:
https://doi.org/10.21149/13065Palabras clave:
anti-SARS-CoV-2, SARS-CoV-2, Covid-19, antibodies, persistence, follow upResumen
Objective. To describe the humoral response in a cohort with mild and asymptomatic SARS-CoV-2 infection previously identified in a community-based serological survey. Materials and methods. This study was an observational follow up of 193 subjects previously identified with positive anti-SARS-CoV-2 antibodies invited for a second test 112 days after the first sampling. All completed a standardized electronic questionnaire. IgM/IgG antibodies were determined using a qualitative IgM/IgG chemiluminescent immunoassay. Results. Among the 193 eligible subjects, a total of 174 (90%) attended the follow-up visit, and their serum samples were tested. Of the samples, 171 (98.3%) were still positive, and 3 (1.7%) were negative. Also, the cut-off index (COI) value of the immunoassay significantly increased from the first to the second test (P <0.001). Conclusions. Our findings support a sustained humoral response in individuals with mild and asymptomatic SARS-CoV-2 infection up to 112 days after a positive serologic baseline test, accompanied by increasing antibody titers.
Descargas
Citas
Lai CC, Wang JH, Hsueh PR. Population-based seroprevalence surveys of anti-SARS-CoV-2 antibody: An up-to-date review. Int J Infect Dis. 2020;101:314-22. https://doi.org/10.1016/j.ijid.2020.10.011
Rostami A, Sepidarkish M, Leeflang MMG, Riahi SM, Shiadeh MN, Esfandyari S, et al. SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis. Clin Microbiol Infect. 2020;27(3):331-40. https://doi.org/10.1016/j.cmi.2020.10.020
Murchu EO, Byrne P, Walsh KA, Carty PG, Conolly M, De Gascun C, et al. Immune response following infection with SARS-CoV-2 and other coronaviruses: A rapid review. Rev Med Virol. 2021;31(2):e2162. https://doi.org/10.1002/rmv.2162
Cevik M, Kuppalli K, Kindrachuk J, Peiris M. Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ. 2020;371:m3862. https://doi.org/10.1136/bmj.m3862
Moore JP, Offit PA. SARS-CoV-2 Vaccines and the growing threat of viral variants. JAMA. 2021;325(9):821-2. https://doi.org/10.1001/jama.2021.1114
Raman R, Patel KJ, Ranjan K. COVID-19: unmasking emerging SARS-CoV-2 variants, vaccines and therapeutic strategies. Biomolecules. 2021;11(7):993. https://doi.org/10.3390/biom11070993
Kellam P, Barclay W. The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection. J Gen Virol. 2020;101(8):791-7. https://doi.org/10.1099/jgv001439
Iyer AS, Jones FK, Nodoushani A, Kelly M, Becker M, Slater D, et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol. 2020;5(52):eabe0367. https://doi.org10.1126/sciimmunol.abe0367
Figueiredo-Campos P, Blankenhaus B, Mota C, Gomes A, Serrano M, Ariotti S, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset. Eur J Immunol. 2020;50(12):2025-40. https://doi.org/10.1002/eji.202048970
Malfertheiner SF, Brandstetter S, Roth S, Harner S, Buntrock-Döpke H, Toncheva AA, et al. Immune response to SARS-CoV-2 in health care workers following a COVID-19 outbreak: A prospective longitudinal study. J Clin Virol. 2020;130:104575. https://doi.org/10.1016/j.jcv.2020.104575
Marklund E, Leach S, Axelsson H, Nyström K, Norder H, Bemark M, et al. Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders. PLoS One. 2020;15(10):e0241104. https://doi.org/10.1371/journal.pone.0241104
Risch M, Weber M, Thiel S, Grossmann K, Wohlwend N, lung T, et al. Temporal course of SARS-CoV-2 antibody positivity in patients with COVID-19 following the first clinical presentation. Biomed Res Int. 2020;2020:9878453. https://doi.org/10.1155/2020/9878453
Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. MedRxiv [preprint]. 2020. https://doi.org/10.1101/2020.07.14.20151126
Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliot J, Hofmann C, Hausner MA, et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med. 2020;383(11):1085-7. https://doi.org/10.1056/NEJMx200017
Liang L, Yang B, Jiang N, Fu W, He X, Zhou Y, et al. Three-month follow-up study of survivors of coronavirus disease 2019 after discharge. J Korean Med. 2020;35(47):e418. https://doi.org/10.3346/jkms.2020.35.e418
Milani GP, Dioni L, Favero C, Cantone L, Macchi C, Delbue S, et al. Serological follow-up of SARS-CoV-2 asymptomatic subjects. Sci Rep. 2020;10(1):20048. https://doi.org/10.1038/s41598-020-77125-8
Moncunill G, Mayor A, Santano R, Jiménez A, Vidal M, Tortajada M, et al. SARS-CoV-2 seroprevalence and antibody kinetics among health care workers in a Spanish hospital after three months of follow-up. J Infect Dis. 2021;223(1):62-71. https://doi.org/10.1093/infdis/jiaa696
Self WH, Tenforde MW, Stubblefield WB, Feldstein LR, Steingrub JS, Shapiro NI, et al. Decline in SARS-CoV-2 antibodies after mild infection among frontline health care personnel in a multistate hospital network - 12 states, April-August 2020. Morb Mortal Wkly Rep. 2020;69(47):1762-6. https://doi.org/10.15585/mmwr.mm6947a2
Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel K, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol. 2020;5(12):1598-607. https://doi.org/10.1038/s41564-020-00813-8
Díaz-Salazar C, Sánchez-García A, Rodríguez-Gutiérrez R, Camacho- Ortiz A, Saldívar-Rodríguez D, González-González JG. Prevalence and associated characteristics of anti-SARS-CoV-2 antibodies in Mexico 5 months after pandemic arrival. BMC Infect Dis. 2021;21(1):835. https://doi.org/10.1186/s12879-021-06550-5
Chan CW, Parker K, Tesic V, Baldwin A, Tan NY, van Wijk X, et al. Analytical and clinical evaluation of the automated elecsys anti-SARS-CoV-2 antibody assay on the Roche cobas e602 Analyzer. Am J Clin Pathol. 2020;154(5):620-6. https://doi.org/10.1093/ajcp/aqaa155
R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria: R, 2020 [cited 2021 Feb 12]. Available from: https://www.R-project.org/
Sanchez A. Serological follow up of positive SARS-CoV-2 case: Supplementary Material 2022. figshare. Figures. https://doi.org/10.6084/m9.figshare.19651017.v1
Patel MM, Thornburg NJ, Stubblefield WB, Talbot HK, Coughlin MM, Feldstein LR, et al. Change in antibodies to SARS-CoV-2 Over 60 days among health care personnel in Nashville, Tennessee. JAMA. 2020;324(17):1781-2. https://doi.org/10.1001/jama.2020.18796
Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26(8):1200-4. https://doi.org/10.1038/s41591-020-0965-6
Wu J, Liang B, Chen C, Wang H, Fang Y, Shen S, et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. Nat Commun. 2021;12(1):1813. https://doi.org/10.1038/s41467-021-22034-1
Galipeau Y, Greig M, Liu G, Driedger M, Langlois MA. Humoral responses and serological assays in SARS-CoV-2 infections. Front Immunol. 2020;11:610688. https://doi.org/10.3389/fimmu.2020.610688
Batra M, Tian R, Zhang C, Clarence E, Sacher CS, Miranda JN, et al. Role of IgG against N-protein of SARS-CoV2 in COVID19 clinical outcomes. Sci Rep. 2021;11(1):3455. https://doi.org/10.1038/s41598-021-83108-0
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2022 Salud Pública de México
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
Al proponer un trabajo para su publicación, los autores aceptan las condiciones contenidas en las presentes normas y ceden a Salud Pública de México los derechos patrimoniales sobre el artículo en cuestión, a fin de que ésta lo edite, publique, reproduzca, difunda, comercialice, traduzca o autorice su traducción a cualquier idioma.
Los derechos transferidos incluyen la publicación del artículo por cualquier medio, sea éste impreso, magnético o electrónico, o por cualquier otro soporte o medio de difusión que exista o pueda crearse en el futuro, así como la realización de publicaciones mediante la concesión de licencias totales o parciales a terceros.
Los artículos aceptados serán publicados en Salud Pública de México bajo una licencia de Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional.
Los trabajos propuestos deberán ser originales e inéditos, y no podrán presentarse a ninguna otra revista mientras se encuentren sometidos a la consideración de Salud Pública de México.También se reciben trabajos completos publicados previamente en forma de resumen, o trabajos no publicados presentados en congresos o seminarios.
Todos los trabajos serán publicados con pleno conocimiento de los autores.
Los artículos firmados son responsabilidad de los autores y no necesariamente reflejan la opinión de la revista, del Instituto Nacional de Salud Pública o de la institución a la que están afiliados los autores.
